A detailed history of Group One Trading, L.P. transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 7,401 shares of GANX stock, worth $16,800. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,401
Previous 2,001 269.87%
Holding current value
$16,800
Previous $7,000 28.57%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.24 - $3.99 $6,696 - $21,546
5,400 Added 269.87%
7,401 $9,000
Q1 2024

May 10, 2024

SELL
$3.21 - $5.04 $6,214 - $9,757
-1,936 Reduced 49.17%
2,001 $7,000
Q4 2023

Feb 14, 2024

BUY
$2.07 - $3.4 $4,140 - $6,800
2,000 Added 103.25%
3,937 $12,000
Q3 2023

Nov 09, 2023

BUY
$3.19 - $4.68 $3,477 - $5,101
1,090 Added 128.69%
1,937 $6,000
Q2 2023

Aug 09, 2023

BUY
$4.36 - $5.5 $3,692 - $4,658
847 New
847 $3,000

Others Institutions Holding GANX

About Gain Therapeutics, Inc.


  • Ticker GANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,883,400
  • Market Cap $27M
  • Description
  • Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...
More about GANX
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.